Sentences with phrase «ovarian cancer patients with»

Ovarian cancer patients with a history of thyroid disorders may require a heightened level of coordination to manage their diseases effectively.

«Our study suggests a therapeutic benefit for repurposing a well - tolerated inhibitor with limited toxicity to treat a specific group of ovarian cancer patients with high levels of CARM1 expression,» said Sergey Karakashev, Ph.D., first author of the study and a postdoctoral researcher in the Zhang Lab.

In addition, drugs called PARP inhibitors, which have been shown to benefit some ovarian cancer patients with BRCA mutations, may be of use for prostate cancer patients with the gene defects.

Platinum - sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression - free survival.

In addition to being a member of CRI's Clinical Leadership Committee, Dr. Coukos is currently the lead investigator of a CRI - funded clinical trial that is treating ovarian cancer patients with two immunotherapies — MEDI4736, an anti-PD-L1 checkpoint inhibitor, and motolimod, a TLR8 agonist.

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

Not exact matches

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

When examining reproductive cancers, the authors noted that while patients with infertility were 44 percent more likely to die of breast cancer, infertility was not associated with an increased risk of ovarian cancer or death from ovarian or endometrial cancers.

Nanotax works by flipping the script on how paclitaxel is administered to patients and with how it's formulated, potentially making it a more effective and better tolerated treatment for ovarian and other abdominal cancers.

When patients with advanced ovarian cancer become resistant to one drug, clinicians usually prescribe a new drug.

Seventy four percent of enrolled patients were diagnosed with ovarian cancer with tumors that had relapsed and metastasized in the peritoneum, the membrane that lines the abdominal cavity.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.»

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United States.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

One patient, a 46 - year old woman, started the trial with stage 4 ovarian cancer — which generally has a very poor prognosis — following five prior courses of chemotherapy.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

If these proteins are inactive — which is the case in many patients with breast, ovarian or prostate cancer — the result is a flawed repair.

The study evaluated 56 patients with ovarian clear cell adenocarcinoma (CCA), an aggressive form of ovarian cancer that is more likely to be resistant to chemotherapy and to have a poorer prognosis than other forms of this disease.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

«We know that patients with BRCA mutations are at high risk for developing breast, as well as pancreatic, ovarian, prostate and other cancers, and we have learned over time that BRCA plays a very important role in DNA damage repair.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

Importantly, elevated BRCA1 methylation was confined to patients diagnosed with so - called high - grade serous tumors, the most aggressive variant of ovarian cancer, which also is the variant associated with BRCA1 mutations.

Analyzing white blood cells from 934 patients and 1,698 healthy controls, they found BRCA1 methylation among 6.4 % of patients diagnosed with ovarian cancer, contrasting 4.2 % among controls.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lCancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lcancer, as only one in three patients survive for 10 years or longer.

Should the results be confirmed by further studies, it is possible that patients with certain genetic changes in BRCA1 could be identified as being at higher risk of breast and ovarian cancer.

In a study of 40 patients with high grade serous ovarian cancer, the researchers monitored tumour DNA that could be detected in a blood sample taken before each chemotherapy treatment.

This test may be particularly useful for patients with high grade serous ovarian cancer because the mutated cancer gene TP53 is found in more than 99 per cent of patients with this form of the disease.

«In patients with ovarian cancer, we found more pathogenic types of bacteria.»

«Overexpression of one of the lncRNAs, DNM30S, was significantly correlated with worse overall ovarian cancer patient survival,» said Dr. Eischen.

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours.

Researchers are also studying ovarian tissue transplantation for patients with cancer.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

«This aligns with what we see in the clinic, that newly - diagnosed ovarian cancer patients most often already have widespread disease,» says Velculescu.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer patients treated at the Cancer Institute into laboratoryCancer Institute into laboratory mice.

Next, under the supervision of gynecologist Katja Gaarenstroom, the researchers tested OTL38 in 12 patients with ovarian cancer.

The commercial testing occurred because the patients had a severe family history of breast cancer, defined as a family with three or more relatives affected by breast or ovarian cancer.

• Diagnostic laparoscopy for all surgically fit patients with suspected advanced - stage ovarian cancer.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

«We are looking forward to further exploring this combination in ovarian cancer and potentially increasing effective treatment options for our patients with this cancer.»

«Phase I study in patients with pancreatic or ovarian cancer.»

The ENGOT - OV16 / NOVA trial evaluated the efficacy and safety of the PARP inhibitor niraparib as maintenance therapy in patients with recurrent ovarian cancer who respond to platinum - based chemotherapy.

Longer term, they want to quickly diagnose additional cancer types, including ovarian and pancreatic cancers, which are fast - spreading and require early detection for a patient to survive, says Goda, who was recently appointed as a chemistry professor at the University of Tokyo but will continue his research with U.C.L.A..

He concluded: «Once it is approved by the regulatory authorities, I'll consider niraparib for all my patients with recurrent ovarian cancer who respond to platinum regardless of BRCA status.»

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

Recent studies have shown that rucaparib, a PARP inhibitor, effectively treats patients with platinum - sensitive, relapsed, high - grade ovarian cancer harboring a BRCA mutation.

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thCancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thcancer is likely to respond to checkpoint inhibitor therapy.